dengue-virus

Documents about dengue-virus

• Chikungunya virus in dengue-suspected patients: Molecular evidence from the 2019 outbreak in Yangon, Myanmar#152675PLOS
• A Global Perspective on the Emerging Threat of Zika and Dengue Co-infection#143898PLOS
• Outbreak of dengue fever in Ghana: The emergence of DENV-1 serotype#172207PLOS
• ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC)#121468ClinicalTrials.gov
• Spatiotemporal co-circulation of four dengue serotypes across Mexico, 2020–2025: A space-time scan analysis#418983PLOS
• Overall and serotype-specific dengue virus transmission intensity in Mexico, 2016–2023: A modelling study of case-notification data#654080PLOS
• Advances in Nanotechnology-Enabled Optical Biosensors for Dengue Virus Detection: A Systematic Review.#281632Repisalud
• The need for balanced dengue vaccine protection: Insights from Thai surveillance data on four serotypes#219396PLOS
• Safety of and Immune Response of a 2-dose Regimen of rDEN1delta30 Dengue Virus Vaccine#995447ClinicalTrials.gov
• Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults#869995ClinicalTrials.gov
• Therapeutic approaches against dengue virus: current status of vaccines, antivirals, and monoclonal antibodies.#309484PubMed
• Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus#863324ClinicalTrials.gov
• Study of AT-752 in Patients With Dengue Infection#1033470ClinicalTrials.gov
• Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study#825738ClinicalTrials.gov
• Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years#398189ClinicalTrials.gov
• Utility of sentinel surveillance as an early warning system for emerging pathogens in a low-resource setting: Correlations of dengue, chikungunya, Zika, and COVID-19 trends between sentinel and passive surveillance systems in Puerto Rico, 2012–2023#275938PLOS
• The Relationship of Ns1 Antigen Profi Le and Days of Illness in Children with Dengue Virus Infection#1004864Jurnal Ners
• Prospective Study of Infant Dengue#994311ClinicalTrials.gov
• Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh#897032ClinicalTrials.gov
• A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against Dengue Virus#127681ClinicalTrials.gov
• Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003)#833927ClinicalTrials.gov
• Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America#867172ClinicalTrials.gov
• Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America#885496ClinicalTrials.gov
• Suppression of TGF-β/Smad2 signaling by GW788388 enhances DENV-2 clearance in macrophages#1029282Arca Dados Dataverse OAI Archive
• Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule#910923ClinicalTrials.gov
• Dengue virus envelope epitope-specific antibodies are associated with protection from severe dengue#784604Europe PMC
• Antiviral activity of an N-allyl acridone against dengue virus#954378Koc University Digital Collections
• Safety and Immune Response to an Investigational Dengue Type 2 Vaccine#640441ClinicalTrials.gov
• GLS-5700 in Dengue Virus-Naïve Adults#18688ClinicalTrials.gov
• Direct RNA Sequencing of Dengue and Chikungunya Viruses with Ultra-Low Input and Custom Multiplexing#326280HAL (France)
• A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults#234475ClinicalTrials.gov
• Safety and Immunogenicity Study of a Dengue Virus DNA Vaccine#802283ClinicalTrials.gov
• Dengvaxia US Pregnancy Registry#807074ClinicalTrials.gov
• A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (in Puerto Rico)#880249ClinicalTrials.gov
• Dengue nanosensors: a roadmap for clinical viability.#316341Repisalud
• Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 Vaccine#633769ClinicalTrials.gov
• Evaluating the Safety and Effectiveness of a Dengue Virus Vaccine in Healthy Adults#883558ClinicalTrials.gov
• Genomic diversity analysis enables development of pan-Dengue Toehold RNA sensors#18886PLOS
• The spatial structure of dengue transmission in Kamphaeng Phet Thailand#626380PLOS
• Developing an eco-bio-social conceptual framework for dengue virus transmission in Latin America and the Caribbean: An e-Delphi study#411638Figshare
• Virus y hongos: lucha contra las infecciones emergentes que avanzan en silencio#197360Repositorio institucional EdocUR
• This Study Will Describe the Burden of DENgue Fever Virus (DENV) Illness Among Household Members Aged 6 Months to 50 Years of Selected Communities in Latin America and Southeast Asia#272419ClinicalTrials.gov
• Zika Virus and Related Arbovirus Infections in Deferred Blood Donors (ZVADD)#914254ClinicalTrials.gov
• A Phase II Trial of a Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy Adults in Thailand#633758ClinicalTrials.gov
• Economic Impact of Dengue Virus in Mexico Over One Decade: A Systematic Literature Review (2010-2020)#784607Europe PMC
• Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine#1010431ClinicalTrials.gov
• Establishment and characterization of a <i>Wolbachia</i> (<i>w</i>AlbB)-infected <i>Aedes aegypt</i>i line (Tw-Kao) for dengue control#154958PLOS
• The Potential of Chitosan Nanoparticles as a Delivery System for the Expression of Dengue Virus' rE Gene with pEGFP-N1 Vector in HeLa Cells#194492Indonesian Journal of Pharmacy
• Development of electrochemiluminescence immunochromatographic test strips for dengue virus.#781388NCBI PubMed Central
• Clinical Trial of the Safety and Immunogenicity of a Tetravalent Dengue Virus Vaccine Admixture TV005 in the Elderly Aged 50-70 Years in Taiwan#256971ClinicalTrials.gov